This work was financially supported by the R&#38;D Plan of Guangdong Province (PR China) (2016A050503028).

All of the procedures including human blood collection were approved by the Sun Yat-Sen University Ethics Committee.
1. GPC3-S-Fab Design Strategy
<ol>
	<li>Design GPC3-S-Fab by linking a Fab of anti-GPC3 (humanized GC3313) with an anti-CD16 VHH14 (Figure 1).</li>
	<li>Synthesize and clone the VH-CH1-CD16-VHH and VL-CL into the pET26b and pET21a vectors as previously reported12.</li>
</ol>
2. Transformation and Culture
<ol>
	<li>Add 100 ng of pET26b containing VH-CH1-CD16 (Figure 1A) and 100 ng of pET21a containing VL-CL (Figure 1A) into 100 &#181;L of competent BL21 (DE3) cells. Mix well and incubate on ice for 30 min. Incubate in a 42 &#176;C water bath for 45 - 90 s, transfer, and incubate on ice for 3 - 5 min.</li>
	<li>Add 500 &#181;L of lysogeny broth (LB) medium into a tube containing BL21 (DE3) cells and then incubate at 37 &#176;C, 150 rpm for 45 - 60 min. Spread 100 &#181;L of BL21 (DE3) cells on LB-agar plates containing 50 &#181;g/mL of kanamycin and 100 &#181;g/mL of ampicillin, and then incubate at 37 &#176;C for 12 - 16 h.
	<ol>
		<li>Prepare lysogeny broth (LB) medium: 1% wt/vol tryptone, 0.5% wt/vol yeast extract, 1% wt/vol NaCl.</li>
	</ol>
	</li>
	<li>Inoculate cells from a single colony into 5 mL of super broth (SB) medium containing 50 &#181;g/mL of kanamycin and 100 &#181;g/mL of ampicillin, and culture at 37 &#176;C, 220 rpm, overnight. Then, inoculate 1 mL of culture into 100 mL of SB medium containing 50 &#181;g/mL of kanamycin and 100 &#181;g/mL of ampicillin and culture at 37 &#176;C, 220 rpm for 4 h. Then, transfer 10 mL of the culture into 1 L of SB medium containing 50 &#181;g/mL of kanamycin and 100 &#181;g/mL of ampicillin and culture at 37 &#176;C, 220 rpm.
	<ol>
		<li>Prepare super broth medium: 3.2% wt/vol tryptone, 2% wt/vol yeast extract, 0.5% wt/vol NaCl.</li>
	</ol>
	</li>
	<li>When the OD600 reaches 0.6 - 0.8, add isopropyl-b-D-thio-galactopyranoside (IPTG) to a final concentration of 0.2 mM. Culture at 16 &#176;C, 180 rpm for 36 - 48 h for periplasmic expression.</li>
</ol>
3. GPC3-S-Fab Periplasmic Purification
<ol>
	<li>Periplasmic fraction preparation
	<ol>
		<li>Collect cells by centrifuging at 4,000 x g, 4 &#176;C for 30 min, discard the medium, and weigh the cells.</li>
		<li>Resuspend the cells thoroughly in 4 mL of ice-cold sucrose solution (20 mM of Tris-HCl, pH 7.5; 25% (wt/vol) sucrose and 1 mM of EDTA) per gram of cells, and incubate on ice for 15 min.</li>
		<li>Centrifuge at 8,500 x g (table top centrifuge, fixed angle rotor), 4 &#176;C for 20 min. Remove the supernatant (the sucrose fraction) and save it on ice.</li>
		<li>Resuspend the pellets in a mix of ice-cold 5 mM of MgCl2 and 1 mM of PMSF (4 mL per gram cells). Add 40 &#181;L of the lysozyme stock (15 mg/mL) per gram, and incubate on ice for 30 min.</li>
		<li>Centrifuge at 8,500 x g (table top centrifuge, fixed angle rotor), 4 &#176;C for 20 min. Transfer the supernatant (the periplasmic fraction) and save it on ice.</li>
		<li>Combine the sucrose fraction and periplasmic fraction, and centrifuge at 30,000 x g, 4 &#176;C for 30 min. Remove the supernatant and save it in a 50 mL conical tube on ice.</li>
	</ol>
	</li>
	<li>Ni-NTA affinity purification
	<ol>
		<li>Resuspend 1 mL of Ni-NTA agarose by mixing thoroughly to achieve a homogeneous suspension, remove 1 mL of Ni-NTA agarose to a fresh 15 mL conical tube, and add 10 column volumes (CV) equilibration buffer (25 mM of Tris-HCl, pH 7.5; 1 M of NaCl) to equilibrate.</li>
		<li>Centrifuge at 400 x g for 5 min, and remove the supernatant carefully. Then, add the Ni-NTA agarose into the 50 mL tube containing the sucrose fraction and periplasmic fraction. Rock at 4 &#176;C for 2 h.</li>
		<li>Centrifuge the mixture at 400 x g, 4 &#176;C for 5 min. Carefully remove the supernatant to another fresh ice-cold tube as the unbound fraction. Transfer the Ni-NTA agarose into a gravity column.</li>
		<li>Add 10 CV of washing buffer (25 mM of Tris-HCl, pH 7.5; 1 M of NaCl; 20 mM, 30 mM or 40 mM of imidazole) to the column, and collect the elute as the washing fraction. 
		NOTE: These solutions should be added in order of increasing concentrations of imidazole.</li>
		<li>Add 3 CV of elution buffer (25 mM of Tris-HCl, pH 7.5; 300 mM of NaCl; 100 mM, 200 mM, 300 mM or 400 mM of imidazole) to the column and collect the elute as Elution fraction 1, 2, 3, and 4. 
		NOTE: These solutions should be added in order of increasing concentrations of imidazole.</li>
		<li>Dialysis the eluted fractions in 2 L of PBS (137 mM of NaCl, 2.7 mM of KCl, 10 mM of Na2HPO4, 2 mM of KH2PO4, pH 7.4) using dialysis tubing (12.4 kDa) at 4 &#176;C for 2 h. Check the presence of GPC3-S-Fab by 12% SDS-PAGE and then by Coomassie blue staining.</li>
	</ol>
	</li>
	<li>IgG-CH1 affinity purification
	<ol>
		<li>Transfer 1 mL of IgG-CH1 affinity resin into a 50 mL conical tube, and wash the beads with PBS first. Then, add the dialyzed solution containing GPC3-S-Fab after Step 3.2.6. Rock at 4 &#176;C for 2 h.</li>
		<li>Centrifuge at 400 x g for 5 min, 4 &#176;C. Carefully remove the supernatant to another fresh ice-cold tube, and transfer the resin to a gravity column.</li>
		<li>Add 10 CV of washing buffer (PBS) to the column, and collect the elution as the wash fraction.</li>
		<li>Prepare the collection tubes by adding 1 M of Tris pH 9.0 (0.1 mL per mL of each eluted fraction). Elute with 3 CV elution buffer (0.1 M of glycine-HCl, pH 2.7), and collect the eluted fraction; repeat 3 times.</li>
		<li>Dialysis the eluted fractions in 2 L of PBS using dialysis tubing (12.4 kDa) at 4 &#176;C for 2 h. Repeat twice.</li>
		<li>Determine the protein concentration by ultramicrospectrophotometer (Molar extinction coefficient: 91105. 1 A280&#160;= 0.69 mg/L).</li>
	</ol>
	</li>
</ol>
4. SDS-PAGE and Western-blotting Analysis
<ol>
	<li>Take a 10 &#181;L of the sample into 5x SDS loading buffer and mix well. Boil the protein mixture at 100 &#176;C for 5 min.
	<ol>
		<li>Prepare 5x SDS loading buffer: 250 mM of Tris-HCl, pH 6.8, 10% wt/vol SDS, 0.5% wt/vol bromophenol blue, 50% vol/vol glycerol, 5% vol/vol beta-mercaptoethanol.</li>
	</ol>
	</li>
	<li>Prepare an SDS-PAGE gel with a loading gel (5%) and separation gel (12%) as previously described26,27,28.</li>
	<li>Load 10 &#181;L of the boiled protein mixture and protein marker, and run the SDS-PAGE.</li>
	<li>Stain the gel by shaking for 20 min with Coomassie brilliant blue solution, and then perform destaining.</li>
	<li>For western blotting, after transferring to a PVDF membrane, block the membrane with TBST (20 mM of Tris-HCl, 150 mM of NaCl, 0.1% vol/vol Tween 20) + 5% wt/vol skim milk for 1 h at room temperature while shaking.</li>
	<li>Incubate the membrane with primary antibodies (anti-His or anti-Flag) diluted 1:2,000 in TBST + 5% skim milk for 1 h.</li>
	<li>Wash with TBST for 5 min at room temperature, and repeat 3 times.</li>
	<li>Incubate the membrane in secondary antibody (HRP-linked anti-mouse Fc antibody) diluted 1:2,000 in TBST + 5% skim milk for 1 h.</li>
	<li>Wash with TBST for 5 min at room temperature, and repeat 3 times.</li>
	<li>Add 1 mL of HPR substrate per film, develop and take images.</li>
</ol>
5. Gel Filtration Analysis
<ol>
	<li>Use the following column: Column volume of 24 mL; Equilibration buffer of PBS pH 7.4; Flow rate of 0.5 mL/min at room temperate; Sample volume of 200 &#181;L.</li>
	<li>Use the following protein volume and concentration: 500 &#181;L of 1.2 mg/mL GPC3-S-Fab. Centrifuge at 20,000 x g for 30 min, and take 200 &#181;L to load.</li>
	<li>For the protein marker volume and concentration, take 100 &#181;L of cytochrome C (2 mg/mL, 12.4 kDa), 140 &#181;L of anhydrase (3 mg/mL, 29 kDa), 140 &#181;L of albumin (10 mg/mL, 66 kDa) and 200 &#181;L of alcohol dehydrogenase (5 mg/mL, 150 kDa) into one tube. Centrifuge at 20,000 x g for 30 min, and take 200 &#181;L to load.</li>
	<li>Before each run, wash with at least 2 CV of distilled water at a flow rate of 0.5 mL/min.</li>
	<li>Equilibrate the column with at least 2 CV of equilibration buffer (PBS, pH 7.4) at a flow rate of 0.5 mL/min.</li>
	<li>Automatically inject the sample at 0.5 mL/min to load the sample.</li>
	<li>Elute with equilibration buffer at 0.5 mL/min and detect at 280 and 215 nm.</li>
</ol>
6. Flow Cytometry Analysis
<ol>
	<li>Culture the HepG2 (GPC3 positive), Hep3B (GPC3 positive), Huh7 (GPC3 positive), and MHCC-97H (GPC3 negative) cells in 100 mm x 20 mm plastic dishes containing DMEM medium with 10% fetal bovine serum (FBS), penicillin (100 &#181;g/mL), and streptomycin (50 &#181;g/mL) at 37 &#176;C, 5% CO2.</li>
	<li>Culture CHO (GPC3 negative) cells and CHO/GPC3 cells harboring the full-length human GPC3 cDNA (GPC3 positive) in 100 mm x 20 mm plastic dishes containing RPMI 1640 medium with 10% FBS, penicillin (100 &#181;g/mL), and streptomycin (50 &#181;g/mL) at 37 &#176;C, 5% CO2.</li>
	<li>Culture the NK92/CD16 harboring the full-length human CD16 cDNA (CD16 positive) in 25cm2 flask containing RPMI 1640 medium with 10% FBS, penicillin (100 &#181;g/mL), and streptomycin (50 &#181;g/mL) at 37 &#176;C, 5% CO2.</li>
	<li>When the cells are 70 - 90% confluent, discard the medium and wash the cells with 2 mL of PBS. Add 1 mL of 0.25% trypsin and incubate at 37 &#176;C for 2 - 3 min (or until the cells start to detach from the surface). Add 1 mL of the complete growth medium to neutralize the trypsin and re-suspend the cells by gently pipetting up and down.</li>
	<li>Count the cell numbers using a Neubauer hemocytometer and detect the cell viability by Trypan Blue.</li>
	<li>Collect 3 x 106 cells for each cell line. Add 1 mL of PBS + 0.2% BSA to re-suspend the cells. Centrifuge at 200 x g, 4 &#176;C for 5 min. Repeat twice.</li>
	<li>Add 0.3 mL of PBS + 0.2% BSA to re-suspend the cells, and transfer 100 &#181;L (approximately 1 million) to each 5 mL polystyrene round-bottom tube. 
	NOTE: Please make sure all steps from here to the tubes should be kept cold on ice. When the antibody is binding to the cell surface antigen, the complex will start to internalize. By keeping it cold, the process is slowed significantly.</li>
	<li>Add 10 &#181;L of primary antibodies (GPC3-S-Fab or human IgG1, final concentration 5 &#181;g/mL) to every tube, and incubate on ice for 1 h.</li>
	<li>Add 1 mL of PBS + 0.2% BSA to wash, and centrifuge at 200 x g, 4 &#176;C for 5 min. Repeat three times.</li>
	<li>Re-suspend in 100 &#181;L of PBS + 0.2% BSA, and then add 0.5 &#181;L of secondary antibody (anti-human IgG(H+L)-488, final concentration 10 &#181;g/mL) and incubate on ice for 1 h. NOTE: From this step, please keep the cells from the light.</li>
	<li>Add 1 mL of PBS + 0.2% BSA to wash, and centrifuge at 200 x g, 4 &#176;C for 5 min. Repeat three times.</li>
	<li>Analyze the cells by flow cytometer according to the standard protocol29. Acquire cells with a 488 nm laser for excitation.</li>
</ol>
7. Cytotoxic Assays
<ol>
	<li>Prepare tumor cells.
	<ol>
		<li>Culture HepG2, Hep3B, Huh7, MHCC-97H, and CHO cell lines as described in steps 6.1 - 6.5.</li>
		<li>Dilute cells to 0.5 &#215; 105/mL, and plate 100 &#181;L cells (5,000 cells per well) on 96-well plates. Culture 6 - 8 h to allow the cells to attach.</li>
	</ol>
	</li>
	<li>Prepare human peripheral blood mononuclear cells (PBMCs).
	<ol>
		<li>Dilute fresh prepared blood with an equal volume of PBS in a 50 mL conical tube. For example, dilute 10 mL of blood with 10 mL of PBS.</li>
		<li>Take 15 mL of lymphocyte separation medium into a fresh 50 mL conical tube. Transfer the diluted blood onto the lymphocyte separation medium along the tube side slowly. 
		NOTE: Keep the tube vertical. Do not break the surface of the lymphocyte separation medium.</li>
		<li>Centrifuge at 400 x g for 35 min at room temperature with the brake off.</li>
		<li>Slowly remove the upper plasma layer, and take the white blood layer containing PBMCs at the plasma-lymphocyte separation medium interface.</li>
		<li>Dilute the PBMCs with a double volume of PBS + 2% FBS. Centrifuge at 400 x g for 5 min.</li>
		<li>Wash the cells twice with PBS + 2% FBS. Centrifuge at 400 x g for 5 min. Count the cell numbers as described in step 6.5.</li>
	</ol>
	</li>
	<li>Prepare NK cells.
	<ol>
		<li>Prepare the PBMCs suspension at a concentration of 5 x 107 cells/mL in PBS + 2% FBS, and place them in a 5 mL polystyrene round-bottom tube.</li>
		<li>Add Human NK cell Enrichment Cocktail at 50 &#181;L/mL of cells. Mix well, and incubate at room temperature for 10 min.</li>
		<li>Resuspend the Magnetic Particles from the NK cell Enrichment kit, and mix well to ensure they are uniformly suspended by pipetting up and down vigorously more than 5 times. Transfer the resuspended Magnetic Particles at 100 &#181;L/mL to the cell suspension. Mix well, and incubate at room temperature for 5 min.</li>
		<li>Bring the cell suspension up to a total volume of 2.5 mL by adding PBS + 2% FBS. Mix the cells in the tube by gently pipetting up and down 2 - 3 times. Place the tube (without a cap) into the magnet. Let the magnetic beads settle down for 2.5 min at room temperature.</li>
		<li>Remove the magnet. In one continuous motion, invert the tube, pouring off the enriched cell suspension into a new tube.</li>
		<li>Count the cell numbers as described in step 6.5.</li>
	</ol>
	</li>
	<li>Set up the cytotoxic reaction.
	<ol>
		<li>Dilute the NK cells to 5 &#215; 105 cells/mL using the corresponding culture medium. Add 100 &#181;L of NK cell suspension to the tumor cells plated on a 96-well plate.</li>
		<li>Add 10 &#181;L of GPC3-S-Fab at different concentrations, with the highest dose at a final concentration of 30 &#181;g/mL, 3-fold dilution, 9 point (three replicates).</li>
		<li>Incubate at 37 &#176;C, 5% CO2 for 72 h.</li>
		<li>After 72 h of incubation, remove the medium, and add 100 &#181;L of DMEM medium containing 10 &#181;L of CCK8 reagent to each well in 96-well plates, and then incubate at 37 &#176;C.</li>
		<li>Read the plate at 450 nm at 1, 2, 3, and 4 h after adding the CCK8 reagent.</li>
		<li>Analyze the data. Calculate the survival rate as (OD450 GPC3-S-Fab + Effector + tumor - OD450 medium)/(OD450 tumor - OD450 medium) &#215; 100% and (OD450 GPC3-S-Fab + tumor - OD450 medium)/(OD450 tumor - OD450 medium) &#215; 100%. The effector cells are NK cells.</li>
	</ol>
	</li>
</ol>

<ol>
	<li>Weiner, G. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Building+better+monoclonal+antibody-based+therapeutics.">Building better monoclonal antibody-based therapeutics.</a> Nature Reviews Cancer. 15 (6), 361-370 (2015).</li><li>Rathi, C., Meibohm, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Clinical+pharmacology+of+bispecific+antibody+constructs.">Clinical pharmacology of bispecific antibody constructs.</a> The Journal of Clinical Pharmacology. 55, S21-S28 (2015).</li><li>Weidle, U. H., Kontermann, R. E., Brinkmann, U. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor-antigen-binding+bispecific+antibodies+for+cancer+treatment.">Tumor-antigen-binding bispecific antibodies for cancer treatment.</a> Seminars in Oncology. 41 (5), 653-660 (2014).</li><li>Demarest, S. J., Glaser, S. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Antibody+therapeutics,+antibody+engineering,+and+the+merits+of+protein+stability.">Antibody therapeutics, antibody engineering, and the merits of protein stability.</a> Current Opinion in Drug Discovery and Development. 11 (5), 675-687 (2008).</li><li>Mabry, R., Snavely, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Therapeutic+bispecific+antibodies:+The+selection+of+stable+single-chain+fragments+to+overcome+engineering+obstacles.">Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.</a> IDrugs. 13 (8), 543-549 (2010).</li><li>Rothlisberger, D., Honegger, A., Pluckthun, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Domain+interactions+in+the+Fab+fragment:+a+comparative+evaluation+of+the+single-chain+Fv+and+Fab+format+engineered+with+variable+domains+of+different+stability.">Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability.</a> Journal of Molecular Biology. 347 (4), 773-789 (2005).</li><li>Kijanka, M., Dorresteijn, B., Oliveira, S., van Bergen en Henegouwen, P. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Nanobody-based+cancer+therapy+of+solid+tumors.">Nanobody-based cancer therapy of solid tumors.</a> Nanomedicine (London). 10 (1), 161-174 (2015).</li><li>Muyldermans, S., Cambillau, C., Wyns, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Recognition+of+antigens+by+single-domain+antibody+fragments:+the+superfluous+luxury+of+paired+domains.">Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains.</a> Trends in Biochemical Sciences. 26 (4), 230-235 (2001).</li><li>Gonzalez-Sapienza, G., Rossotti, M. A., Tabares-da Rosa, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Single-Domain+Antibodies+As+Versatile+Affinity+Reagents+for+Analytical+and+Diagnostic+Applications.">Single-Domain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications.</a> Frontiers in Immunology. 8, 977 (2017).</li><li>Fernandes, C. F. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Camelid+Single-Domain+Antibodies+As+an+Alternative+to+Overcome+Challenges+Related+to+the+Prevention,+Detection,+and+Control+of+Neglected+Tropical+Diseases.">Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases.</a> Frontiers in Immunology. 8, 653 (2017).</li><li>Li, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+novel+bispecific+antibody,+S-Fab,+induces+potent+cancer+cell+killing.">A novel bispecific antibody, S-Fab, induces potent cancer cell killing.</a> Journal of Immunotherapy. 38 (9), 350-356 (2015).</li><li>Li, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+single-domain+antibody-linked+Fab+bispecific+antibody+Her2-S-Fab+has+potent+cytotoxicity+against+Her2-expressing+tumor+cells.">A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.</a> AMB Express. 6 (1), 32 (2016).</li><li>Nakano, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Anti-glypican+3+antibodies+cause+ADCC+against+human+hepatocellular+carcinoma+cells.">Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.</a> Biochemical and Biophysical Research Communications. 378 (2), 279-284 (2009).</li><li>Behar, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Isolation+and+characterization+of+anti-FcgammaRIII+(CD16)+llama+single-domain+antibodies+that+activate+natural+killer+cells.">Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells.</a> Protein Engineering, Design, and Selection. 21 (1), 1-10 (2008).</li><li>Baral, T. N., Arbabi-Ghahroudi, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Expression+of+single-domain+antibodies+in+bacterial+systems.">Expression of single-domain antibodies in bacterial systems.</a> Methods in Molecular Biology. 911, 257-275 (2012).</li><li>Arbabi-Ghahroudi, M., Tanha, J., MacKenzie, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prokaryotic+expression+of+antibodies.">Prokaryotic expression of antibodies.</a> Cancer and Metastasis Reviews. 24 (4), 501-519 (2005).</li><li>Spiess, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bispecific+antibodies+with+natural+architecture+produced+by+co-culture+of+bacteria+expressing+two+distinct+half-antibodies.">Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.</a> Nature Biotechnology. 31 (8), 753-758 (2013).</li><li>Filmus, J., Selleck, S. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Glypicans:+proteoglycans+with+a+surprise.">Glypicans: proteoglycans with a surprise.</a> Journal of Clinical Investigation. 108 (4), 497-501 (2001).</li><li>Baumhoer, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Glypican+3+expression+in+human+nonneoplastic,+preneoplastic,+and+neoplastic+tissues:+a+tissue+microarray+analysis+of+4,387+tissue+samples.">Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.</a> American Journal of Clinical Pathology. 129 (6), 899-906 (2008).</li><li>Llovet, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+molecular+signature+to+discriminate+dysplastic+nodules+from+early+hepatocellular+carcinoma+in+HCV+cirrhosis.">A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.</a> Gastroenterology. 131 (6), 1758-1767 (2006).</li><li>Zhu, Z. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Enhanced+glypican-3+expression+differentiates+the+majority+of+hepatocellular+carcinomas+from+benign+hepatic+disorders.">Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.</a> Gut. 48 (4), 558-564 (2001).</li><li>Hsu, H. C., Cheng, W., Lai, P. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cloning+and+expression+of+a+developmentally+regulated+transcript+MXR7+in+hepatocellular+carcinoma:+biological+significance+and+temporospatial+distribution.">Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution.</a> Cancer Research. 57 (22), 5179-5184 (1997).</li><li>Flaherty, M. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Nonclinical+evaluation+of+GMA161--an+antihuman+CD16+(FcgammaRIII)+monoclonal+antibody+for+treatment+of+autoimmune+disorders+in+CD16+transgenic+mice.">Nonclinical evaluation of GMA161--an antihuman CD16 (FcgammaRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.</a> Toxicological Sciences. 125 (1), 299-309 (2012).</li><li>Sharma, R., Das, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Organ-specific+phenotypic+and+functional+features+of+NK+cells+in+humans.">Organ-specific phenotypic and functional features of NK cells in humans.</a> Immunological Research. 58 (1), 125-131 (2014).</li><li>Li, X. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effect+of+CD16a,+the+surface+receptor+of+Kupffer+cells,+on+the+growth+of+hepatocellular+carcinoma+cells.">Effect of CD16a, the surface receptor of Kupffer cells, on the growth of hepatocellular carcinoma cells.</a> International Journal of Molecular Medicine. 37 (6), 1465-1474 (2016).</li><li>Fiala, G. J., Schamel, W. W., Blumenthal, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Blue+native+polyacrylamide+gel+electrophoresis+(BN-PAGE)+for+analysis+of+multiprotein+complexes+from+cellular+lysates.">Blue native polyacrylamide gel electrophoresis (BN-PAGE) for analysis of multiprotein complexes from cellular lysates.</a> Journal of Visualized Experiments. (48), (2011).</li><li>Hwang, A. C., Grey, P. H., Cuddy, K., Oppenheimer, D. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pouring+and+running+a+protein+gel+by+reusing+commercial+cassettes.">Pouring and running a protein gel by reusing commercial cassettes.</a> Journal of Visualized Experiments. (60), (2012).</li><li>Laemmli, U. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cleavage+of+structural+proteins+during+the+assembly+of+the+head+of+bacteriophage+T4.">Cleavage of structural proteins during the assembly of the head of bacteriophage T4.</a> Nature. 227 (5259), 680-685 (1970).</li><li>Menon, V., Thomas, R., Ghale, A. R., Reinhard, C., Pruszak, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Flow+cytometry+protocols+for+surface+and+intracellular+antigen+analyses+of+neural+cell+types.">Flow cytometry protocols for surface and intracellular antigen analyses of neural cell types.</a> Journal of Visualized Experiments. (94), (2014).</li><li>Feng, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Therapeutically+targeting+glypican-3+via+a+conformation-specific+single-domain+antibody+in+hepatocellular+carcinoma.">Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.</a> Proceedings of the National Academy of Science U S A. 110 (12), E1083-E1091 (2013).</li></ol>

The authors declare no conflicts of interest.

In this study, we present a strategy to construct a new format of bsAbs, GPC3-S-Fab, which can recruit NK cells targeting GPC3 positive tumor cells. The S-Fab is based on the natural Fab format by adding an anti-CD16 VHH11,12. Compared with the bsAbs containing Fc region, GPC3-S-Fab can easily be produced in the periplasm of bacteria on a large scale.
Using the expression and purification strategy described in the protocol, we obtained...

Monoclonal antibodies are now broadly used for cancer treatment1. Due to the flexibility of antibodies, various antibody-based formats have been actively explored. Compared with monoclonal antibodies, bsAbs have two different antigen binding modules, enabling them to recognize two different targets simultaneously and efficiently trigger the recruitment of immune effector cells to target and kill tumor cells2.
Current recombinant bsAb formats can be generally assigned to two classes: Fc-containing bsAbs and bsAbs without an Fc region. Compared with Fc-containing formats that are mostly produced in mammalian cells, bsAbs without an Fc region have the advantages of smaller sizes, are more readily produced in microorganism expression systems, and can penetrate tumor tissues more efficiently3.
bsAbs without an Fc region are commonly formed by linking individual binding moieties, such as single-chain variable fragments (scFvs) or Fabs3. Without the stabilizing domains, bsAbs based on scFv fragments often have compromised thermal stability, low solubility, or an increased potential for aggregation4,5. In contrast, Fab-based bsAbs are more stable due to the heterodimerization of the CH1 and CL in the native Fab moiety4,6.
Variable domain from heavy-chain-only antibodies (VHHs, also referred to as single domain antibodies) are the active antigen-binding fragment of natural heavy chain antibodies7. VHHs have the characteristics of high affinity, specificity of conventional IgGs8, low immunogenicity, and high yields in bacterial expression9. Compared with Fv fragments, VHHs have higher thermal stability10. Compared with Fab moieties, VHHs have smaller sizes due to the lack of CH1 and CL. Thus, S-Fab, the bsAb format obtained by linking the Fab with a single domain antibody, VHH, was designed and studied for its anti-tumor effects11,12.
In this study, the construction of GPC3-S-Fab by linking the Fab of hGC3313 with an anti-CD16a VHH14 was described. The GPC3-S-Fab can be efficiently produced by periplasmic expression in Escherichia coli (E. coli). Functional studies of GPC3-S-Fab suggested that GPC3-S-Fab is a promising strategy for liver cancer therapy. Thus, the advantages of GPC3-S-Fab over alternative techniques with applicable references to previous studies include easy production and purification, and more stable bsAbs.
Mammalian expression systems and prokaryotic expression systems have been used to express various formats of BsAbs. In contrast to mammalian expression systems, E. coli-based protein expression systems have many benefits, including high yields, low cost and labor-saving, the ease of genetic manipulations, and high transformation efficiency15. For bsAbs expression in E. coli, there are two basic strategies: expression in the cytoplasm and expression in the periplasm between the cytoplasm and outer cell membranes15. Compared to the reducing environment of cytoplasm, the periplasm is a more oxidizing environment, which promotes the correct folding and co-expression of proteins16. Correct folding plays a key role in solubility, stability and function generation of bsAbs. Therefore, a signal sequence pelB was added to the N-terminus of the S-Fab to direct secretion to the periplasm of E. coli17. To ensure correct folding, solubility, thermal stability, and conformational stability, reducing the complexity and the size of an antibody is frequently employed16. The S-Fab format consists of one Fab and one VHH, which is expressed very well in bacterial systems likely due to the simple structure and small size.
GPC3 was chosen in this GPC3-S-Fab bispecific antibody format. Glypican-3 (GPC3) is a member of the heparin sulfate (HS) proteoglycan family that is anchored to the cell surface through glycosylphosphatidylinositol (GPI)18. GPC3 is overexpressed in 70% of hepatocellular carcinoma (HCC) cases, which account for the majority of liver cancers19,20,21,22. Because GPC3 is rarely expressed in normal tissues, GPC3 has been proposed as a potential target for HCC. Multiple mouse mAbs have been produced against GPC3. However, only GC33 exhibited limited anti-tumor activity 22, and it failed to exhibit clinical efficacy in patients. In this study, GPC3-S-Fab was shown to be able to recruit NK cells to kill GPC3 tumor cells14.
To recruit NK cells, anti-CD16 VHH was used. CD16a is a low affinity IgG receptor, expressed mainly on natural killer (NK) cells, macrophages, monocytes and some subtypes of T cells. It is involved in antibody-dependent cell cytotoxicity (ADCC) by NK cells23. Human NK cells can be categorized into two types, CD56-CD16+ and CD56+CD16-. In contrast to CD56+CD16&#8722; NK cells, CD56-CD16+ NK cells can release higher levels of perforin and granzyme B and thus present a strong cytotoxicity24. Kupffer cells (KCs), expressing CD16a, are the resident macrophages in liver. Kupffer cells play an important role in the suppression of liver cancer25. Thus, bsAbs targeting CD16a may be a more promising strategy than engaging T cells against liver cancer.

<table><tbody><tr><td>Shaking incubator</td><td>Thermo Fisher</td><td>MAXQ 4000</td><td></td></tr><tr><td>Shaking incubator</td><td>Zhicheng</td><td>ZWYR-D2402</td><td></td></tr><tr><td>Centrifuge</td><td>Cence</td><td>GL-10MD</td><td></td></tr><tr><td>Centrifuge</td><td>Beckman coulter</td><td>Avanti j-26S XPI</td><td></td></tr><tr><td>Centrifuge</td><td>eppendorf</td><td>5810R</td><td></td></tr><tr><td>Ultraviolet spectrophotometer</td><td>Thermo Fisher</td><td>Nanodrop</td><td></td></tr><tr><td>Analytical polyacrylamide gel electrophoresis apparatus</td><td>Mini-PROTEAN&amp;reg; Tetra</td><td>Bio-rad</td><td></td></tr><tr><td>Trans-blot apparatus</td><td>Criterion</td><td>Bio-rad</td><td></td></tr><tr><td>Imaging system</td><td>Bio-rad</td><td>chemidoc tm XRS+</td><td></td></tr><tr><td>Fast Protein Liquid chromatogram</td><td>GE Healthcare</td><td>AKTA avant</td><td></td></tr><tr><td>GF column</td><td>GE Healthcare</td><td>28-9909-44 Superdex 200 Increase 10/300 GL</td><td></td></tr><tr><td>Flow Cytometer</td><td>Beckman coulter</td><td>FC500</td><td></td></tr><tr><td>Centrifuge</td><td>eppendorf</td><td>5702R</td><td></td></tr><tr><td>Envision plate reader</td><td>TECAN</td><td>Infinite F50</td><td></td></tr><tr><td>Anti His-tag</td><td>eBioscience</td><td>14-6657-82</td><td></td></tr><tr><td>anti-Flag-tag</td><td>Sigma</td><td>F1804</td><td></td></tr><tr><td>anti-human(H&amp;amp;L)-488</td><td>A11013</td><td>Invitrogen</td><td></td></tr><tr><td>Anti-mouse IgG HRP-linked antibody</td><td>Cell Signaling</td><td>7076S</td><td></td></tr><tr><td>Ni-NTA-Agarose</td><td>Tribioscience</td><td>TBS9202-100</td><td></td></tr><tr><td>IgG-CH1 affinity resin</td><td>Thermo Fisher</td><td>194320005</td><td></td></tr><tr><td>Ficoll-Plaque Plus</td><td>GE Healthcare</td><td>17-1440-03</td><td></td></tr><tr><td>NK cell enrichment kit</td><td>Stemcell</td><td>19055</td><td></td></tr><tr><td>Magnet</td><td>Stemcell</td><td>18000</td><td></td></tr><tr><td>CCK8 kit</td><td>Dojindo</td><td>CK04</td><td></td></tr><tr><td>DMEM</td><td>Gibco</td><td>C11995500CP</td><td></td></tr><tr><td>RPMI-1640</td><td>Gibco</td><td>C11875500CP</td><td></td></tr><tr><td>Fetal Bovine Serum (FBS)</td><td>Sigma</td><td>F2442</td><td></td></tr><tr><td>Trypsin</td><td>Gibco</td><td>15050-057</td><td></td></tr><tr><td>Penicillin-Streptomycin</td><td>Gibco</td><td>15140-122</td><td>Cell culture</td></tr><tr><td>Standard marker</td><td>Sigma Aldrich</td><td>MWGF200</td><td>Gel filtration</td></tr><tr><td>Isopropyl-b-D-thio-galactopyranoside (IPTG)</td><td>VWR chemicals</td><td>VWRC0487-100G</td><td></td></tr><tr><td>Dialysis tubing</td><td>Sigma Aldrich</td><td>D0655-100FT</td><td></td></tr><tr><td>Knanamycine</td><td>VWR</td><td>VWRC0408-100G</td><td></td></tr><tr><td>Ampicillin</td><td>VWR</td><td>VWRC0339-100G</td><td></td></tr><tr><td>Tryptone</td><td>Thermo Fisher</td><td>LP0042B</td><td></td></tr><tr><td>Yeast Extract</td><td>Thermo Fisher</td><td>LP0021B</td><td></td></tr><tr><td>NaCl</td><td>Sangon Biotech</td><td>A100241</td><td></td></tr><tr><td>Trizma base</td><td>Sigma Aldrich</td><td>T6791-1KG</td><td></td></tr><tr><td>EDTA</td><td>Sigma Aldrich</td><td>V900106</td><td></td></tr><tr><td>Glycine</td><td>aladdin</td><td>A110752-500g</td><td></td></tr><tr><td>KCl</td><td>aladdin</td><td>P112134-500g</td><td></td></tr><tr><td>MgCl</td><td>Sigma Aldrich</td><td>V900020</td><td></td></tr><tr><td>Agar</td><td>Sangon Biotech</td><td>A505255-0250</td><td></td></tr><tr><td>Potassium Phosphate, Monobasic Anhydrous (KH2PO4)</td><td>VWR</td><td>7778-77-0</td><td></td></tr><tr><td>Sodium Phosphate, Dibasic, Anhydrous (Na2HPO4)</td><td>VWR</td><td>7558-79-4</td><td></td></tr><tr><td>2-Mercaptoethanol</td><td>VWR</td><td>60-24-2</td><td></td></tr><tr><td>Phenylmethyl Sulfonyl Fluoride (PMSF)</td><td>VWR</td><td>329-98-6</td><td></td></tr><tr><td>Lysozyme</td><td>Sigma Aldrich</td><td>L6876-25G</td><td></td></tr><tr><td>Coomassie Brilliant Blue R250</td><td>VWR</td><td>VWRC0472-50G</td><td></td></tr><tr><td>Bromophenol blue</td><td>Sangon Biotech</td><td>A500922-25G</td><td></td></tr><tr><td>Bovine Serum Albumin (BSA)</td><td>VWR</td><td>VWRC0332-100G</td><td></td></tr><tr><td>Glycerol</td><td>Sigma Aldrich</td><td>V900122</td><td></td></tr><tr><td>100mm x 20mm plastic dish</td><td>Corning</td><td>430167</td><td></td></tr><tr><td>25cm2 flask</td><td>Corning</td><td>430639</td><td></td></tr><tr><td>96 well cell culture cluster</td><td>Corning</td><td>3599</td><td></td></tr><tr><td>Sucrose</td><td>Sangon Biotech</td><td>A610498-0005</td><td></td></tr><tr><td>CHO</td><td>the Type Culture Collection of the Chinese Academy of Sciences</td><td>GNHa 3</td><td></td></tr><tr><td>MHCC-97H</td><td>the Type Culture Collection of the Chinese Academy of Sciences</td><td>SCSP-528</td><td></td></tr><tr><td>HepG2</td><td>the Type Culture Collection of the Chinese Academy of Sciences</td><td>TCHu 72</td><td></td></tr><tr><td>Huh7</td><td>the Type Culture Collection of the Chinese Academy of Sciences</td><td>TCHu182</td><td></td></tr><tr><td>Hep3B</td><td>the Type Culture Collection of the Chinese Academy of Sciences</td><td>TCHu106</td><td></td></tr><tr><td>NK92</td><td>ATCC</td><td>CRL2408</td><td></td></tr></tbody></table>

a gpc3-targeting bispecific antibody, gpc3-s-fab, with potent cytotoxicity

This protocol describes the construction and functional studies of a bispecific antibody (bsAb), GPC3-S-Fab. bsAbs can recognize two different epitopes through their two different arms. bsAbs have been actively studied for their ability to directly recruit immune cells to kill tumor cells. Currently, the majority of bsAbs are produced in the form of recombinant proteins, either as Fc-containing bsAbs or as smaller bsAb derivatives without the Fc region. In this study, GPC3-S-Fab, an antibody fragment (Fab) based bispecific antibody, was designed by linking the Fab of anti-GPC3 antibody GC33 with an anti-CD16 single domain antibody. The GPC3-S-Fab can be expressed in Escherichia coli and purified by two affinity chromatographies. The purified GPC3-S-Fab can specifically bind to and kill GPC3 positive liver cancer cells by recruiting natural killer cells, suggesting a potential application of GPC3-S-Fab in liver cancer therapy.

GPC3-S-Fab purification
GPC3-S-Fab was purified from E. coli by a two-step affinity purification, first with Ni-NTA-agarose, followed by IgG-CH1 affinity purification. After the two-step affinity purification, GPC3-S-Fab was purified to homogeneity with the two chains close to 1:1 (Figure 2A). The presence of both VH-CH1-CD16 VHH and VL-CL polypeptides can be identified by ...

Watch this Scientific Journal Video about A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity at JoVE.com

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Here, we present a protocol to produce a bispecific antibody GPC3-S-Fab in Escherichia coli. The purified GPC3-S-Fab has potent cytotoxicity against GPC3 positive liver cancer cells.

This protocol describes the construction and functional studies of a bispecific antibody (bsAb), GPC3-S-Fab. bsAbs can recognize two different epitopes ...

a-gpc3-targeting-bispecific-antibody-gpc3-s-fab-with-potent

Research

JoVE Journal

Cancer Research

8.6K Views.  Sun Yat-Sen University. Hier presenteren we een protocol om te produceren een antilichaam bispecifieke GPC3-S-Fab in Escherichia coli. Het gezuiverde GPC3-S-Fab heeft krachtige cytotoxiciteit tegen GPC3 positieve lever kankercellen.

Video: A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Monoclonal antibodies are high affinity multifunctional drugs that work by variable independent mechanisms to eliminate cancer cells. Over the last few decades, the field of antibody-drug conjugates, bispecific antibodies, chimeric antigen receptors (CAR) and cancer immunotherapy has emerged as the most promising area of basic and therapeutic investigations. With numerous successful human trials targeting immune checkpoint receptors and CAR-T cells in leukemia and melanoma at a breakthrough pace, it is highly exciting times for oncologic therapeutics derived from variations of antibody engineering. Regrettably, a significantly large numbers of antibody and CAR based therapeutics have also proven disappointing in human trials of solid cancers because of the limited availability of immune effector cells in the tumor bed. Importantly, nonspecific distribution of therapeutic antibodies in tissues other than tumors also contribute to the lack of clinical efficacy, associated toxicity and clinical failure. As faithful translation of preclinical studies into human clinical trails are highly relied on mice tumor xenograft efficacy and safety studies, here we highlight a method to test the tumor and general tissue distribution of therapeutic antibodies. This is achieved by labeling the protein-A purified antibody with near Infrared fluorescent dye followed by live imaging of tumor bearing mice.

Here we present a protocol to study the in vivo localization of antibodies in mice tumor xenograft models.

Monoclonal antibodies are high affinity multifunctional drugs that work by variable independent mechanisms to eliminate cancer cells. Over the last few ...

Preparation of Site-Specific Cytotoxic Protein Conjugates via Maleimide-thiol Chemistry and Sortase A-Mediated Ligation

Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as growth factor receptors on their surface. This feature enables development of highly selective therapeutics, the protein bioconjugates, composed of targeting proteins (antibodies or receptor ligands) connected to highly cytotoxic drugs by a specific linker. Due to very high affinity and selectivity of targeting proteins the bioconjugates recognize marker proteins on the cancer cells surface and utilize receptor-mediated endocytosis to reach the cell interior. Intracellular vesicular transport system ultimately delivers the bioconjugates to the lysosomes, where proteolysis separates free cytotoxic drugs from the proteinaceous core of the bioconjugates, triggering drug-dependent cancer cell death. Currently, there are several protein bioconjugates approved for cancer treatment and large number is under development or clinical trials.
One of the main challenges in the generation of the bioconjugates is a site-specific attachment of the cytotoxic drug to the targeting protein. Recent years have brought a tremendous progress in the development of chemical and enzymatic strategies for protein modification with cytotoxic drugs. Here we present the detailed protocols for the site-specific incorporation of cytotoxic warheads into targeting proteins using a chemical method employing maleimide-thiol chemistry and an enzymatic approach that relies on sortase A-mediated ligation. We use engineered variant of fibroblast growth factor 2 and fragment crystallizable region of human immunoglobulin G as an exemplary targeting proteins and monomethyl auristatin E and methotrexate as model cytotoxic drugs. All the described strategies allow for highly efficient generation of biologically active cytotoxic conjugates of defined molecular architecture with potential for selective treatment of diverse cancers.

Here we provide detailed protocols for a site-specific labeling of proteins with cytotoxic drugs using maleimide-thiol reaction and sortase A-mediated ligation.

Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as ...

Biochemistry

Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique

Recent developments in tissue engineering offer innovative solutions for many diseases. For example, tissue engineering using induced pluripotent stem cell (iPS) emerged as a new method in regenerative medicine. Although this tissue regeneration is promising, contamination with unwanted cells during tissue cultures is a major concern. Moreover, there is a safety concern regarding tumorigenicity after transplantation. Therefore, there is an urgent need for eliminating specific cells without damaging other cells that need to be protected, especially in established tissue. Here, we present a method for specific cell elimination from a mixed 3D cell culture in vitro with near infrared photoimmunotherapy (NIR-PIT) without damaging non-targeted cells. This technique enables the elimination of specific cells from mixed cell cultures or tissues.

Eliminating specific cells without damaging other cells is extremely difficult, especially in established tissue, yet there is an urgent need for a cell elimination method in the tissue engineering field. Here, we present a method for specific cell elimination from a mixed 3D cell culture using near infrared photoimmunotherapy (NIR-PIT).

Recent developments in tissue engineering offer innovative solutions for many diseases. For example, tissue engineering using induced pluripotent stem ...

Bioengineering

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

T cell-engaging bispecific antibodies (T-BsAbs) are in various stages of preclinical development and clinical testing for solid tumors. Factors such as valency, spatial arrangement, interdomain distance, and Fc mutations affect the anti-tumor efficacy of these therapies, commonly by influencing the homing of T cells to tumors, which remains a major challenge. Here, we describe a method to transduce activated human T cells with luciferase, allowing in vivo tracking of T cells during T-BsAb therapy studies. The ability of T-BsAbs to redirect T cells to tumors can be quantitatively evaluated at multiple time points during treatment, allowing researchers to correlate the anti-tumor efficacy of T-BsAbs and other interventions with the persistence of T cells in tumors. This method alleviates the need to sacrifice animals during treatment to histologically assess T cell infiltration and can be repeated at multiple time points to determine the kinetics of T cell trafficking during and after treatment.

Here, we describe a method for transducing human T cells with luciferase to facilitate in vivo tracking of bispecific antibody-induced T cell trafficking to tumors in studies to evaluate the anti-tumor efficacy and mechanism of T cell-engaging bispecific antibodies.

T cell-engaging bispecific antibodies (T-BsAbs) are in various stages of preclinical development and clinical testing for solid tumors. Factors such as ...

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Immunotherapy with antigen-specific antibodies or immune checkpoint inhibitors has revolutionized the therapy of breast cancer. Breast cancer cells expressing the epidermal growth factor receptor HER2 can be targeted by the anti-HER-2 antibody trastuzumab. Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism implicated in the antitumor action of HER-2. Trastuzumab bound to cancer cells can be recognized by the Fc receptors of ADCC effector cells (e.g., natural killer (NK) cells, macrophages, and granulocytes), triggering the cytotoxic activity of these immune cells leading to cancer cell death. We set out to develop an image-based assay for the quantification of ADCC to identify novel ADCC modulator compounds by high-content screening. In the assay, HER2 overexpressing JIMT-1 breast cancer cells are co-cultured with NK-92 cells in the presence of trastuzumab, and target cell death is quantified by automated microscopy and quantitative image analysis. Target cells are distinguished from effector cells based on their EGFP fluorescence. We show how compound libraries can be tested in the assay to identify ADCC modulator drugs. For this purpose, a compound library test plate was set up using randomly selected fine chemicals off the lab shelf. Three microtubule destabilizing compounds (colchicine, vincristine, podophyllotoxin) expected to interfere with NK cell migration and degranulation were also included in the test library. The test screen identified all three positive control compounds as hits proving the suitability of the method to identify ADCC-modifying drugs in a chemical library. With this assay, compound library screens can be performed to identify ADCC-enhancing compounds that could be used as adjuvant therapeutic agents for the treatment of patients receiving anticancer immunotherapies. In addition, the method can also be used to identify any undesirable ADCC-inhibiting side effects of therapeutic drugs taken by cancer patients for different indications.

This protocol presents an automated, image-based high-throughput technique to identify compounds modulating natural killer cell-mediated breast cancer cell killing in the presence of a therapeutic anti-HER-2 antibody.

Immunotherapy with antigen-specific antibodies or immune checkpoint inhibitors has revolutionized the therapy of breast cancer. Breast cancer cells ...

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Monoclonal antibody-based immunotherapy targeting tumor antigens is now a mainstay of cancer treatment. One of the clinically relevant mechanisms of action of the antibodies is antibody-dependent cellular cytotoxicity (ADCC), where the antibody binds to the cancer cells and engages the cellular component of the immune system, e.g., natural killer (NK) cells, to kill the tumor cells. The effectiveness of these therapies could be improved by identifying adjuvant compounds that increase the sensitivity of the cancer cells or the potency of the immune cells. In addition, undiscovered drug interactions in cancer patients co-medicated for previous conditions or cancer-associated symptoms may determine the success of the antibody therapy; therefore, such unwanted drug interactions need to be eliminated. With these goals in mind, we created a cancer ADCC model and describe here a simple protocol to find ADCC-modulating drugs. Since 3D models such as cancer cell spheroids are superior to 2D cultures in predicting in vivo responses of tumors to anticancer therapies, spheroid co-cultures of EGFP-expressing HER2+ JIMT-1 breast cancer cells and the NK92.CD16 cell lines were set up and induced with Trastuzumab, a monoclonal antibody clinically approved against HER2-positive breast cancer. JIMT-1 spheroids were allowed to form in cell-repellent U-bottom 96-well plates. On day 3, NK cells and Trastuzumab were added. The spheroids were then stained with Annexin V-Alexa 647 to measure apoptotic cell death, which was quantitated in the peripheral zone of the spheroids with an automated microscope. The applicability of our assay to identify ADCC-modulating molecules is demonstrated by showing that Sunitinib, a receptor tyrosine kinase inhibitor approved by the FDA against metastatic cancer, almost completely abolishes ADCC. The generation of the spheroids and image acquisition and analysis pipelines are compatible with high-throughput screening for ADCC-modulating compounds in cancer cell spheroids.

Here, we present a method to identify compounds that modulate the ADCC mechanism, an important cancer cell-killing mechanism of antitumor antibodies. The cytotoxic effect of NK cells is measured in breast cancer cell spheroids in the presence of Trastuzumab. Image analysis identifies live and dead killer and target cells in spheroids.

Monoclonal antibody-based immunotherapy targeting tumor antigens is now a mainstay of cancer treatment. One of the clinically relevant mechanisms of ...

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Chimeric antigen receptor (CAR) T-cell therapy for cancer has achieved significant clinical benefit for resistant and refractory hematological malignancies such as childhood acute lymphocytic leukemia. Efforts are currently underway to extend this promising therapy to solid tumors in addition to other hematological cancers. Here, we describe the development and production of potent CAR T cells targeting antigens with unique or preferential expression on solid and liquid tumor cells. The in vitro potency of these CAR T cells is then evaluated in real-time using the highly sensitive impedance-based xCELLigence assay. Specifically, the impact of different costimulatory signaling domains, such as glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR), on the in vitro potency of CAR T cells is examined. This report includes protocols for: generating CAR T cells for preclinical studies using lentiviral gene transduction, expanding CAR T cells, validating CAR expression, and running and analyzing xCELLigence potency assays.

We describe a quantitative real-time in vitro cytolysis assay system to evaluate the potency of chimeric antigen receptor T cells targeting liquid and solid tumor cells. This protocol can be extended to assess other immune effector cells, as well as combination treatments.

Chimeric antigen receptor (CAR) T-cell therapy for cancer has achieved significant clinical benefit for resistant and refractory hematological ...

Immunology and Infection

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Elimination of harmful antibodies from organisms is a valuable approach for the intervention of antibody-associated diseases, such as Dengue hemorrhagic fever and autoimmune diseases. Since thousands of antibodies with different epitopes are circulating in blood, no universal method, except for the dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF), was reported to target specific harmful antibodies. The development of DCAF molecules makes significant contribution to the progress of targeted therapy, which were demonstrated to eliminate the antibody dependent enhancement (ADE) effect in a Dengue virus (DENV) infection model and to boost the acetylcholine receptor activity in a myasthenia gravis model. Here, we describe a protocol for the synthesis of a DCAF molecule (DCAF1), which can selectively block 4G2 antibody to attenuate ADE effect during Dengue virus infection, and illustrate the binding of DCAF1 to 4G2 antibody by an ELISA assay. In our method, DCAF1 is synthesized by the conjugation of a hydrazine derivative of a Fc-III peptide and a recombinant expressed long &#945;-helix with antigenic sequence through native chemical ligation (NCL). This protocol has been successfully applied to DCAF1 as well as other DCAF molecules for targeting their cognate antibodies.

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) is novel for the elimination of harmful antibodies. Here, we describe a detailed protocol for the synthesis of DCAF1 molecule, which can selectively block 4G2 antibody to eliminate antibody dependent enhancement effect during Dengue virus infection.

Elimination of harmful antibodies from organisms is a valuable approach for the intervention of antibody-associated diseases, such as Dengue hemorrhagic ...

Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies

One mechanism of action for clinical efficacy by therapeutic antibodies is the promotion of immune-related functions, such as cytokine secretion and cytotoxicity, driven by Fc&#947;RIIIa (CD16) expressed on natural killer (NK) cells. These observations have led to research focusing on methods to increase Fc receptor-mediated events, which include removal of a fucose moiety found on the Fc portion of the antibody. Further studies have elucidated the mechanistic changes in signaling, cellular processes, and cytotoxic characteristics that increase ADCC activity with afucosylated antibodies. Additionally, other studies have shown the potential benefits of these antibodies in combination with small molecule inhibitors. These experiments demonstrated the molecular and cellular mechanisms underlying the benefits of using afucosylated antibodies in combination settings. Many of these observations were based on an artificial in vitro activation assay in which the Fc&#947;RIIIa on human NK cells was activated by therapeutic antibodies. This assay provided the flexibility to study downstream effector NK cell functions, such as cytokine production and degranulation. In addition, this assay has been used to interrogate signaling pathways and identify molecules that can be modulated or used as biomarkers. Finally, other therapeutic molecules (i.e., small molecule inhibitors) have been added to the system to provide insights into the combination of these therapeutics with therapeutic antibodies, which is essential in the current clinical space. This manuscript aims to provide a technical foundation for performing this artificial human NK cell activation assay. The protocol demonstrates key steps for cell activation as well as potential downstream applications that range from functional readouts to more mechanistic observations.

A protocol for studying Fc&#947;RIIIa-driven events by therapeutic antibodies in human natural killer cells is described here. This artificial stimulation platform permits the interrogation of downstream effector functions such as degranulation, chemokine/cytokine production, and signaling pathways mediated by the Fc&#947;RIIIa and Fc portions of antibodies involved in binding.

One mechanism of action for clinical efficacy by therapeutic antibodies is the promotion of immune-related functions, such as cytokine secretion and ...

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Natural killer (NK) cells are innate immune cells that play a crucial role in the body's defense against tumors and viral infections. The generation of human induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) expressing NK cells has emerged as a promising avenue for "off the shelf" cancer immunotherapy. Here, we utilized an NK cell-optimized CAR construct that includes the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3&#950; signaling domain, which has been demonstrated to stimulate robust antigen-specific NK cell-mediated antitumor activity. The use of iPSCs for CAR NK cell generation offers several advantages, including homogenous CAR expression, scalability, reproducibility, and the potential for clinical application. This detailed step-by-step protocol from cell engineering to differentiation enables the generation of NK cell-optimized iPSC-derived CAR-expressing NK cells, providing a standardized and targeted cancer immunotherapy with improved antitumor activity and highlighting their potential as a promising treatment option for various malignancies.

Here, we present a method to differentiate and expand human iPSC-derived chimeric antigen receptor (CAR)-expressing natural killer cells with improved killing against various malignancies. This protocol demonstrates the differentiation and expansion of natural killer (NK) optimized iPSC-derived CAR-NK cells and the measurement of antitumor activity against various tumor cell lines.

Natural killer (NK) cells are innate immune cells that play a crucial role in the body's defense against tumors and viral infections. The generation of ...

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Samenvatting

Meer video's verkennen

Hoofdstukken in deze video